author-photo

Perttu Koskenvesa

University of Helsinki
Helsinki University Central Hospital

58

Papers

1506

Citations

Citation Trend

Filter By

Papers (47) Sort By

Journal Conference Others

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.

2021 European Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Ponatinib‐induced ichthyosiform eruption

2021
Show All
- Source
- Cite
- Save
Citations (0)
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses

2020 Leukemia
Show All
- Source
- Cite
- Save
Citations (7)
Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

2020 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (2)
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

2020 Leukemia
Show All
- Source
- Cite
- Save
Citations (13)
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

2020 Blood Advances
Show All
- Source
- Cite
- Save
Citations (17)
Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

2019 OncoImmunology
Show All
- Source
- Cite
- Save
Citations (11)
A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines

2018 Blood
Show All
- Source
- Cite
- Save
Citations (1)